ClinicalTrials.gg

Program

VP-001

A development code.

Its studies are mostly in Retinal Dystrophies, led by PYC Therapeutics.

Furthest: phase 2, since Feb 20, 20253 company-led studies, 1 open or runningNext primary completion: Mar 8, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PYC Therapeutics31 open or runningphase 2since Feb 20, 2025May 25, 2023Mar 8, 2028phase 2 · NCT06852963

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 25, 2023First study: phase 1 study in Retinal DystrophiesFirst studyNCT05902962 · 17 enrolled · United States
  2. Jun 3, 2024Phase 1 study in Retinitis Pigmentosa 11NCT06455826 · 6 enrolled · United States
  3. Feb 20, 2025Phase 2 study in Retinitis Pigmentosa 11NCT06852963 · 17 enrolled · United States

Ahead

  1. Mar 8, 2028Primary completion: phase 2 study in Retinitis Pigmentosa 11NCT06852963

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06852963Retinitis Pigmentosa 11 · United States2Active, not recruitingMar 8, 202817
NCT06455826Retinitis Pigmentosa 11 · United States1CompletedSep 24, 20256
NCT05902962Retinal Dystrophies · United States1CompletedAug 8, 202517

How it is read

Names in the registry

  • “VP-001”, 3 entries

Codes read as this program: VP001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.